Ifosfamide

Essential medicine status

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

EMLc | ATC codes: L01AA06

Indication	Ewing sarcoma of bone or articular cartilage of unspecified sites ICD11 code: 2B52.Z
INN	Ifosfamide
Medicine type	Chemical agent
List type	Complementary
Formulations	**Parenteral > General injections > IV:** 500 mg in vial powder for injection ; 1 g in vial powder for injection ; 2 g in vial powder for injection
EML status history	First added in 2009 (TRS 958) Changed in 2015 (TRS 994)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Cancer
Wikipedia	Ifosfamide
DrugBank	Ifosfamide

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for ifosfamide on the complementary list of the EML for use in treatment protocols for Ewing sarcoma was specifically endorsed. Additionally, ifosfamide was added on the complementary list of the EMLc for this indication. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for Ewing sarcoma is attached.